Healx is an AI-powered, patient-inspired tech company, accelerating the discovery and development of rare disease treatments at scale. There are 7,000 known rare diseases that affect over 400 million people across the globe but only 5% of those conditions have approved treatments. Healx’s mission is to identify and progress novel therapies for the 95% of rare diseases currently without an approved treatment.
Accelerating treatments for rare diseases

Get to know Healx

  • Headquartered in: Cambridge, Cambridgeshire, England

  • Founded in: 2014

  • Sector: Artificial Intelligence, Biopharma, Biotechnology, Health Care, Medical

  • Investor: Private Investor Network

To do this, Healx created Healnet, an AI-driven drug discovery platform. Healnet integrates data from multiple sources, including biomedical research, scientific literature and Healx’s own curated proprietary information, to form the world’s most detailed rare disease knowledge graph. This graph is then analysed by the team’s innovative AI models, which leverage a deep understanding of human disease biology, to uncover new drug-disease relationships. The team combines this technology with drug discovery expertise and patient insight to identify existing drugs that may be repurposed and combined to treat rare diseases.

This innovative approach means treatments can be found more quickly, efficiently and cost-effectively than traditional drug discovery methods allow. Healx was founded in 2014 in Cambridge, UK, by Dr Tim Guilliams, a Biochemical Engineer and tech entrepreneur, and Dr David Brown, co-inventor of Viagra and former Global Head of Drug Discovery at Roche. In 2019, Healx raised $56 million in Series B funding. In 2020, the company was listed in Tech Nation’s Future Fifty cohort and won 5 prizes at the CogX Awards including Grand Jury Prize and Best AI Product.

Press enter or esc to cancel